On second thought, the FDA figures it no longer needs to discuss Exelixis’ application for Cabometyx in neuroendocrine tumors ...

Amid his fight with a rare form of cancer, Bobby Patterson has the backing and support from his best friend and longtime ...

AMT-676 is under clinical development by Multitude therapeutics and currently in Phase I for Neuroendocrine Tumors.

Identical to MIB1. ‡ Gastrointestinal neuroendocrine tumor. § Pancreatic neuroendocrine tumor. NET: Neuroendocrine tumor. Data from [20,94]. T1 Tumor limited to the pancreas and size <2 cm T2 ...

SEATTLE, Jan. 10, 2025 (GLOBE NEWSWIRE) -- ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers ...

This new funding positions NRMA Insurance as the first corporate partner to support a McGrath Cancer Care Nurse since the ...

Despite concerns over cabozantinib's patent expiry, Exelixis projects robust future revenues, with lead pipeline candidate ...

Award follows extensive pre-clinical, single agent activity data generated by Prof. Colleen Nelson's lab at QUT in 'Aggressive Variant' prostate ca ...

Cabometyx is under clinical development by Exelixis and currently in Phase II for Salivary Gland Cancer. According to GlobalData, Phase II drugs for Salivary Gland Cancer have a 14% phase transition ...

H.C. Wainwright analyst Robert Burns raised the firm’s price target on Exelixis (EXEL) to $40 from $29 and keeps a Buy rating on the shares.

Citi keeps a Buy rating on Exelixis (EXEL) with a $38 price target after the company announced that it has been notified by the FDA that the ...

Exelixis (EXEL) stock in focus as U.S. FDA leaves out an AdCom in its review of the firm's label expansion for cancer therapy ...